Prosecution Insights
Last updated: April 19, 2026
Application No. 17/434,672

COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER

Non-Final OA §102§112
Filed
Aug 27, 2021
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Purdue Research Foundation
OA Round
3 (Non-Final)
76%
Grant Probability
Favorable
3-4
OA Rounds
3y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
83 granted / 109 resolved
+16.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
35 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§102 §112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/4/2025 has been entered. Status of the Claims Claims 1, 6-9, 12-15, and 24-25 are pending. Claims 6-9, 12-14, and 24-25 are withdrawn. Claims 1 and 15 are rejected. Response to Amendments/Arguments Applicant’s amendments and arguments, filed 11/4/2025, with respect to the rejection(s) of claim(s) 1 and 15 under 112(a) and 35 USC 102 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made below with a new matter 112(a) rejection and a new 35 USC 102 rejection. Because all previous rejections were overcome by amendments, Applicant’s 11/4/2025 arguments will not be addressed. Claim Objections Claim 1 is objected to because of the following informalities: The structure in claim 1 has both a “(I)” and a “(III)” next to it. Applicant should clarify with one or the other roman numeral. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 1 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Amended claim 1 has added the following restrictions to the end of the claim: “R1 is hydrogen and R6 is a hydrogen, an alkyl, or an ethanol; or R1 is methyl and R6 is a hydrogen, an ethyl, or an ethanol.” The original disclosure does not support this embodiment/combination. Additionally, the current (withdrawn) claims are drawn to embodiments that do not obey by these rules. See Compound 88 in claim 14: PNG media_image1.png 229 211 media_image1.png Greyscale , wherein R1 is methyl and R6 is butyl. “A claim that omits an element which applicant describes as an essential or critical feature of the invention originally disclosed does not comply with the written description requirement”. See Gentry Gallery, 134 F.3d at 1480, 45 USPQ2d at 1503; In re Sus, 306 F.2d 494, 504, 134 USPQ 301, 309 (CCPA 1962). See MPEP 2163.05(IA). Therefore, this is a new matter rejection. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 and 15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Holland et al. (Journal of Labelled Compounds and Radiopharmaceuticals-XXVII, No. 6, 1989). Regarding instant claim 1, Holland discloses the following compound (norethindrone): PNG media_image2.png 152 227 media_image2.png Greyscale , which is embraced by a compound of instant formula (III): PNG media_image3.png 238 447 media_image3.png Greyscale wherein X = =O; R1 = H; R6 = H; R2 = H; R5=H (see top of p. 630). Regarding instant claim 15, Holland additionally discloses this compound labelled with deuterium and tritium “which utilizes water as the source of the label” (see “Summary”), wherein water is a pharmaceutically acceptable excipient. A skilled artisan would at once envisage a composition with the compound supra and water. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph McKane can be reached at 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 27, 2021
Application Filed
Nov 21, 2024
Non-Final Rejection — §102, §112
Apr 29, 2025
Response Filed
Jun 01, 2025
Final Rejection — §102, §112
Nov 04, 2025
Request for Continued Examination
Nov 05, 2025
Response after Non-Final Action
Nov 24, 2025
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600716
COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12600715
SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12599560
LIPIDS AND LIPID NANOPARTICLE FORMULATIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12582637
NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577213
DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+33.6%)
3y 1m
Median Time to Grant
High
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month